Issues
January 2010 EDITORIAL
- Clinical Guidelines and Performance Measures
L. Gregory Pawlson, MD, MPH; and Thomas H. Lee Jr, MD Although physicians should be aware of guidelines and measures, they need to apply more nuanced approaches when seeing individual patients. Full Text PDF CLINICAL
- New Diabetes HEDIS Blood Pressure Quality Measure: Potential for Overtreatment
Hae Mi Choe, PharmD; Steven J. Bernstein, MD, MPH; Connie J. Standiford, MD; and Rodney A. Hayward, MD The new HEDIS diabetes blood pressure measure may promote performance incentives for overtreatment of blood pressure, causing potential harm, especially in the elderly population. Full Text PDF
- “All-or-None” (Bundled) Process and Outcome Indicators of Diabetes Care
Jay H. Shubrook Jr, DO; Richard J. Snow, DO, MPH; Sharon L. McGill, MPH; and Grace D. Brannan, PhD In this study, providers were more likely to achieve processes-ofcare goals when diabetes care was bundled at the indicator level than at the patient level. Full Text PDF Appendix MANAGERIAL
- Mail-Order Pharmacy Use and Adherence to Diabetes-Related Medications
O. Kenrik Duru, MD, MSHS; Julie A. Schmittdiel, PhD; Wendy T. Dyer, MSc; Melissa M. Parker, MS; Connie S. Uratsu, MS; James Chan, PharmD; and Andrew J. Karter, PhD Patients with diabetes were more likely to have good medication adherence if they refilled their medications by mail versus at localpharmacies. Full Text PDF
- Leveling the Field: Addressing Health Disparities Through Diabetes Disease Management
Richard O. White, MD; Darren A. DeWalt, MD, MPH; Robert M. Malone, PharmD; Chandra Y. Osborn, PhD, MPH; Michael P. Pignone, MD, MPH; and Russell L. Rothman, MD, MPP A subanalysis of a successful algorithm-driven primary care–based diabetes disease management program examines the relationships among patient characteristics, labor inputs, and improvement in A1C level. Full Text PDF
- Is There a Survival Benefit Within a German Primary Care–Based Disease Management Program?
Antje Miksch, MD; Gunter Laux, DSc, MSc; Dominik Ose, MPH; Stefanie Joos, MD; Stephen Campbell, PhD; Burgi Riens, DSc; and Joachim Szecsenyi, MD, MSc Patients with type 2 diabetes in a German disease management program had a lower mortality rate after 3 years than those not in the program. Full Text PDF POLICY
- Physician Utilization by Insurance Type Among Youth With Type 2 Diabetes
Carrie McAdam-Marx, PhD; Robert I. Field, PhD; Stephen Metraux, PhD; Stephen T. Moelter, PhD; and Diana I. Brixner, PhD Physician utilization during the year before the first indication of type 2 diabetes did not differ between Medicaid-covered and privately insured youth. Full Text PDF TRENDS FROM THE FIELD
- A Pay-for-Performance Program for Diabetes Care in Taiwan: A Preliminary Assessment
Tai-Ti Lee, MS; Shou-Hsia Cheng, PhD; Chi-Chen Chen, MS; and Mei-Shu Lai, MD, PhD A pay-for-performance program in Taiwan improved the quality of diabetes care and slightly increased the cost of care. Full Text PDF WEB EXCLUSIVE CONTENT
- Clinical and Economic Outcomes Associated With Potentially Inappropriate Prescribing in the Elderly
Karen M. Stockl, PharmD; Lisa Le, MS; Shaoang Zhang, PhD; and Ann S. M. Harada, PhD Clinical and economic outcomes associated with the use of specific potentially inappropriate medications in the elderly were evaluated. Full Text PDF
- The Effect of a PPO Pay-for-Performance Program on Patients With Diabetes
Judy Y. Chen, MD, MSHS; Haijun Tian, PhD; Deborah Taira Juarez, ScD; Krista A. Hodges, MPH, MBA; Jennifer C. Brand, MPH; Richard S. Chung, MD; and Antonio P. Legorreta, MD, MPH A pay-for-performance program in a preferred provider organization setting may significantly increase the receipt of quality care and decrease hospitalization rates among patients with diabetes. Full Text PDF
- Increasing Copayments and Adherence to Diabetes, Hypertension, and Hyperlipidemic Medications
Matthew L. Maciejewski, PhD; Chris L. Bryson, MD, MS; Mark Perkins, PharmD; David K. Blough, PhD; Francesca E. Cunningham, PhD; John C. Fortney, PhD; Sarah L. Krein, PhD; Kevin T. Stroupe, PhD; Nancy D. Sharp, PhD; and Chuan-Fen Liu, PhD A copayment increase from $2 to $7 adversely affected veterans’ adherence to statins, antihypertensives, and oral hypoglycemic agents. Full Text PDF
|
|